Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc reported results from its 2026 annual general meeting of shareholders. Investors approved amendments to the 2018 Stock Option and Incentive Plan, increasing the ordinary shares authorized for issuance under the plan by 5,900,000. The updated plan is filed as Exhibit 10.1.
Shareholders elected all nine director nominees for one-year terms, with each receiving over 135 million votes in favor in most cases. They also approved, in a non-binding advisory vote, the compensation of named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor, authorizing the Audit and Risk Committee to set its remuneration.
In addition, shareholders renewed the Board’s authority to allot and issue shares under Irish law and renewed authority to disapply statutory pre-emption rights. Overall, the meeting confirmed the company’s current board composition, executive pay program, equity incentive plan, and capital authorization framework.
ALKERMES PLC reported a Schedule 13G/A amendment showing T. Rowe Price Associates, Inc. beneficially owned 4,664,563 shares of Common Stock, representing 2.8% of the class as stated in the filing. The filing lists sole voting power of 4,650,687 shares and sole dispositive power of 4,664,563. The report is signed by Ellen York, Vice President, dated 05/15/2026.
Alkermes plc reported positive phase 3 topline results from the REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary endpoint, showing statistically significant improvement in excessive daytime sleepiness versus placebo on the Epworth Sleepiness Scale (p<0.0001), and met key secondary endpoints PGI-C and IHSS with similar significance.
The safety profile in idiopathic hypersomnia was generally consistent with prior LUMRYZ data, with common adverse events including nausea, headache, anxiety, dizziness and vomiting. Alkermes plans to submit a supplemental New Drug Application to the U.S. FDA by the end of 2026, but under an existing settlement it cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if approved.
Alkermes plc reported a quarterly net loss after completing a large acquisition. For the three months ended March 31, 2026, revenue rose to $392.9 million from $306.5 million, driven by higher product sales including LUMRYZ, which contributed $39.5 million after the Avadel Pharmaceuticals acquisition.
The company recorded a net loss of $66.5 million, or $0.40 per share, compared with net income of $22.5 million a year earlier, mainly due to higher R&D, selling, general and administrative costs, amortization of new intangibles, and increased interest expense tied to new debt.
Alkermes closed the Avadel deal for about $2.31 billion in total preliminary consideration, recognizing $513.0 million of goodwill and $1.79 billion of intangible assets. To fund the transaction, it drew $1.525 billion of new term loans, which increased total assets to $4.26 billion and reduced cash and cash equivalents to $351.6 million.
Alkermes plc reported strong top-line growth but a GAAP loss for Q1 2026 and raised its EBITDA outlook for the year. Total revenues rose to $392.9 million from $306.5 million, driven by proprietary net sales of $338.1 million, including LYBALVI $92.4 million, ARISTADA $93.8 million, VIVITROL $112.4 million and newly acquired LUMRYZ $39.5 million.
The company posted a GAAP net loss of $66.5 million versus GAAP net income of $22.5 million a year earlier, with EBITDA at $(30.1) million and Adjusted EBITDA improving to $80.3 million from $45.6 million. Alkermes closed its acquisition of Avadel Pharmaceuticals in February, using about $775 million of cash and entering into $1.525 billion of term loans due 2031, leaving cash, cash equivalents, restricted cash and investments at $538.2 million versus $1.32 billion at year-end 2025.
For 2026, total revenue guidance of $1.73–$1.84 billion is unchanged, but GAAP net loss expectations improved to $70–$90 million and EBITDA guidance increased to $105–$135 million, while Adjusted EBITDA remains targeted at $370–$410 million. The outlook assumes VIVITROL net sales of $460–$480 million, LYBALVI $380–$400 million, ARISTADA $365–$385 million and LUMRYZ $315–$335 million.
Alkermes plc executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares at $33.20 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. Following this sale, he continues to hold 231,558 Ordinary Shares directly, indicating a substantially larger remaining equity position in the company.
Alkermes plc reported a Form 144 disclosure showing sales of Common Stock by an issuer-associated holder. The filing lists three reported sales on 03/02/2026, 03/03/2026, and 04/06/2026 with amounts 59,575.86, 60,531.84, and 70,315.38 respectively. The record also lists earlier vesting events for restricted stock units and performance share units (355; 844; 776; 59) from 2017–2018.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 ordinary shares at $19.34 per share and then sold 9,000 ordinary shares at a weighted average price of $33.3955 on May 1, 2026.
Both the option exercise and the open-market sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 81,389 ordinary shares, and the exercised options are fully vested in accordance with their terms.
Alkermes plc has amended its prior acquisition filing to add full financial statements for its new subsidiary, Avadel Pharmaceuticals plc, and pro forma combined results. The amendment includes audited Avadel financials for the three years ended December 31, 2025 and Alkermes’ unaudited pro forma condensed combined balance sheet and income statement for 2025.
Avadel’s 2025 results show net product revenue of $279.1 million, up sharply from prior years, driven entirely by narcolepsy drug LUMRYZ. Net income was $64.7 million in 2025 versus losses in 2024 and 2023, while cash and cash equivalents rose to $165.4 million at year-end 2025. Total assets were $285.1 million and shareholders’ equity was $171.3 million.
The notes detail the October 2025 transaction agreement under which Alkermes acquired all Avadel shares for $21.00 per share in cash plus a non-transferable $1.50 per-share contingent value right, and Avadel’s subsequent delisting. They also highlight LUMRYZ’s U.S. approvals, orphan drug exclusivity into 2030 and 2031 for adult and pediatric narcolepsy, a 2025 license deal for sleep-disorder candidate valiloxybate with a $20.0 million upfront payment, and a 2023 royalty financing that carried a 25.4% effective interest rate and a $37.1 million year-end obligation.
Alkermes plc reports insider share dispositions and planned transactions involving ordinary shares. Craig Hopkinson reported three past dispositions of 9,000 shares each on 02/02/2026, 03/02/2026 and 04/01/2026. The filing also lists a broker-assisted cashless exercise for 5,000 shares on 05/01/2026 and vesting of a performance share award of 4,000 shares on 02/05/2026.